ASCO’s CancerLinQ launches SmartLinQ QOPI Certification Pathway

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

ASCO’s CancerLinQ launched the SmartLinQ QOPI Certification Pathway, an application that allows oncology practices to automate quality measure tracking and reporting for participation in ASCO’s Quality Oncology Practice Initiative Certification Program, a three-year certification recognizing practices’ commitment to high-quality care for outpatient oncology practices.

Since 2019, SmartLinQ has enabled CancerLinQ practices to automate their quality activities, derive actionable insights from real-world patient data, and benchmark their care against the CancerLinQ network. The new SmartLinQ QOPI Certification Pathway was recently piloted at four of CancerLinQ’s more than 100 subscribing practices, enabling them to reduce staff time and expenses for quality reporting for QOPI Certification. It is now available for re-certification and maintenance submissions for all QOPI Certified CancerLinQ subscribers.

SmartLinQ’s benefits stem from the automation of quality management functions, beginning with data collection. CancerLinQ automatically and securely takes in and harmonizes and codifies the data from practices’ electronic health record systems, eliminating the need for manual chart abstraction for quality programs like QOPI Certification. New Mexico Cancer Center, one of the SmartLinQ QOPI Certification Pathway pilot practices, saved approximately 100 hours of staff time when using SmartLinQ to automate its recertification for the QOPI Certification Program.

Beyond data abstraction and automated quality reporting for QOPI Certification, SmartLinQ enables practices to:

  • Track progress daily against a broad set of quality measures, both for the practice overall and for specific sites and individual physicians

  • Benchmark care against peers, by querying de-identified patient data on 1.5 million real-world cancer patient records in the CancerLinQ database

  • Identify “actionable patients” who still need specific care or treatment to comply with quality standards, creating opportunities to proactively improve care

  • Identify and fix data quality issues, such as missing or inaccurate data in patients’ EHRs.

Table of Contents

YOU MAY BE INTERESTED IN

For nearly 25 years, business executive Lou Weisbach and urologist Richard J. Boxer have argued that finding the money to finance the cures for devastating diseases is not as difficult as it appears. To start finding the cures, the U.S. Department of the Treasury needs to issue some bonds—$750 billion worth. Next, you hire CEOs—one...

There is general agreement that the United States spends too much on health care, especially on pharmaceuticals.  But what we spend on drugs is not simply a function of price. If eggs double in price, people can simply cut the number of eggs they eat in half.  Simply stated, cost is the product of (price per unit times the number of units purchased). 
What did President Richard M. Nixon and Senator Edward M. Kennedy have in common? They each played a pivotal role in the passage of the National Cancer Act signed by Nixon on Dec. 23, 1971. The NCA established the National Cancer Program authorizing the initial investment in the NCI-designated Cancer Centers Program. 
When I first proposed targeting PCNA (proliferating cell nuclear antigen) as a therapeutic approach, the response I got was: “No one will ever make a drug against PCNA. It’s undruggable.” The protein lacks enzymatic activity, has a disordered region, and binds to over 200 other proteins within the cell. From a traditional drug development perspective, these characteristics made PCNA an impossible target.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login